VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. pyogenes M Protein Vaccine
Vaccine Information
  • Vaccine Name: S. pyogenes M Protein Vaccine
  • Target Pathogen: Streptococcus pyogenes
  • Target Disease: Group A streptococcal infections, Strep throat, Scarlet fever
  • Vaccine Ontology ID: VO_0004053
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: A polypeptide encompassing a conformational B cell epitope of the M protein conjugated with DT (Schulze et al., 2006).
  • emm1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: A polypeptide encompassing a conformational B cell epitope of the M protein (J8, positions 344–355 of the M1 sequence, accession no. X62131) was synthesised, purified and conjugated with DT (Schulze et al., 2006).
    • Detailed Gene Information: Click Here.
  • Adjuvant: cholera toxin B subunit
  • Immunization Route: intranasal immunization
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were immunised by intranasal route (10 μl per nostril) with either J8-DT (M protein) (30 μg per dose) co-administered with 10 μg of CTB or 0.5 μg of the TLR2/6 agonist MALP-2 as mucosal adjuvants, on day 0, 7, 14, and 28. Control animals received PBS alone (Schulze et al., 2006).
  • Challenge Protocol: Mice were intranasally challenged with 108 CFU of the heterologous virulent S. pyogenes strain NS192 in 40 μl of PBS (20 μl per nostril) (Schulze et al., 2006).
  • Efficacy: Mice immunized with J8-DT had 60% survival following challenge (Schulze et al., 2006).
References
Schulze et al., 2006: Schulze K, Olive C, Ebensen T, Guzmán CA. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine. 2006; 24(35-36); 6088-6095. [PubMed: 16828529].